Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antiviral Agents | 14 | 2021 | 364 | 4.130 |
Why?
|
| Hepatitis C | 12 | 2022 | 182 | 4.100 |
Why?
|
| Hepatitis C, Chronic | 8 | 2020 | 95 | 2.620 |
Why?
|
| Hepacivirus | 7 | 2022 | 135 | 2.120 |
Why?
|
| Gastroenterology | 4 | 2021 | 157 | 1.200 |
Why?
|
| Lactulose | 1 | 2023 | 22 | 0.800 |
Why?
|
| Hepatic Encephalopathy | 1 | 2023 | 35 | 0.800 |
Why?
|
| Liver Diseases | 2 | 2016 | 243 | 0.720 |
Why?
|
| Ribavirin | 2 | 2013 | 37 | 0.700 |
Why?
|
| Internship and Residency | 4 | 2021 | 1090 | 0.700 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2021 | 6 | 0.680 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2021 | 20 | 0.680 |
Why?
|
| Off-Label Use | 2 | 2014 | 16 | 0.510 |
Why?
|
| Liver Cirrhosis | 5 | 2017 | 273 | 0.500 |
Why?
|
| Health Services Accessibility | 3 | 2017 | 481 | 0.470 |
Why?
|
| Interferon-alpha | 2 | 2013 | 187 | 0.460 |
Why?
|
| Hepatitis B, Chronic | 1 | 2015 | 34 | 0.450 |
Why?
|
| Informed Consent | 2 | 2020 | 277 | 0.440 |
Why?
|
| Liver Transplantation | 5 | 2023 | 1194 | 0.440 |
Why?
|
| Viral Load | 2 | 2021 | 154 | 0.420 |
Why?
|
| Medicaid | 1 | 2017 | 258 | 0.410 |
Why?
|
| Polyethylene Glycols | 2 | 2013 | 373 | 0.410 |
Why?
|
| Interferons | 1 | 2014 | 112 | 0.400 |
Why?
|
| Humans | 31 | 2023 | 93515 | 0.360 |
Why?
|
| Drug Discovery | 1 | 2013 | 113 | 0.360 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 256 | 0.350 |
Why?
|
| Biliary Tract Diseases | 1 | 2011 | 37 | 0.330 |
Why?
|
| Resource Allocation | 1 | 2011 | 64 | 0.330 |
Why?
|
| Curriculum | 4 | 2021 | 594 | 0.330 |
Why?
|
| Health Care Rationing | 1 | 2011 | 83 | 0.330 |
Why?
|
| Patient Participation | 1 | 2012 | 229 | 0.320 |
Why?
|
| Treatment Outcome | 8 | 2021 | 9099 | 0.290 |
Why?
|
| United States | 8 | 2021 | 7622 | 0.230 |
Why?
|
| Tissue and Organ Procurement | 1 | 2010 | 388 | 0.220 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 486 | 0.200 |
Why?
|
| Liver Neoplasms | 2 | 2020 | 776 | 0.180 |
Why?
|
| Proline | 2 | 2013 | 49 | 0.180 |
Why?
|
| Social Stigma | 1 | 2022 | 86 | 0.180 |
Why?
|
| United States Food and Drug Administration | 2 | 2014 | 142 | 0.180 |
Why?
|
| Vulnerable Populations | 1 | 2022 | 91 | 0.180 |
Why?
|
| Viremia | 1 | 2021 | 51 | 0.170 |
Why?
|
| Oligopeptides | 2 | 2013 | 191 | 0.170 |
Why?
|
| Azathioprine | 1 | 2021 | 122 | 0.160 |
Why?
|
| Donor Selection | 1 | 2021 | 81 | 0.160 |
Why?
|
| Prednisone | 1 | 2021 | 242 | 0.160 |
Why?
|
| Beneficence | 1 | 2020 | 36 | 0.160 |
Why?
|
| Drug Therapy, Combination | 2 | 2014 | 759 | 0.160 |
Why?
|
| Risk Assessment | 4 | 2021 | 2441 | 0.150 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 988 | 0.150 |
Why?
|
| End Stage Liver Disease | 2 | 2017 | 73 | 0.150 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 464 | 0.150 |
Why?
|
| Female | 12 | 2021 | 48702 | 0.140 |
Why?
|
| Glucocorticoids | 1 | 2021 | 362 | 0.140 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2023 | 590 | 0.140 |
Why?
|
| Ethics, Medical | 1 | 2021 | 296 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 836 | 0.140 |
Why?
|
| Tissue Donors | 1 | 2021 | 541 | 0.130 |
Why?
|
| Legislation, Drug | 1 | 2017 | 7 | 0.130 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2017 | 24 | 0.130 |
Why?
|
| Rifamycins | 1 | 2016 | 7 | 0.130 |
Why?
|
| Hepatorenal Syndrome | 1 | 2016 | 9 | 0.120 |
Why?
|
| Paracentesis | 1 | 2016 | 10 | 0.120 |
Why?
|
| Coinfection | 2 | 2015 | 67 | 0.120 |
Why?
|
| Flaviviridae Infections | 1 | 2015 | 1 | 0.120 |
Why?
|
| GB virus C | 1 | 2015 | 1 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 990 | 0.120 |
Why?
|
| Ascites | 1 | 2016 | 54 | 0.120 |
Why?
|
| Internal Medicine | 2 | 2016 | 336 | 0.120 |
Why?
|
| Anti-Infective Agents | 1 | 2016 | 87 | 0.120 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2015 | 20 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 624 | 0.120 |
Why?
|
| Middle Aged | 8 | 2021 | 27573 | 0.120 |
Why?
|
| Waiting Lists | 1 | 2017 | 210 | 0.110 |
Why?
|
| Deficiency Diseases | 1 | 2015 | 12 | 0.110 |
Why?
|
| Male | 10 | 2021 | 44557 | 0.110 |
Why?
|
| Career Choice | 1 | 2016 | 156 | 0.110 |
Why?
|
| Comorbidity | 2 | 2015 | 1007 | 0.110 |
Why?
|
| Liver Failure | 1 | 2015 | 69 | 0.110 |
Why?
|
| Zinc | 1 | 2015 | 99 | 0.110 |
Why?
|
| Drug and Narcotic Control | 1 | 2014 | 6 | 0.100 |
Why?
|
| Time Factors | 4 | 2021 | 5410 | 0.100 |
Why?
|
| Protease Inhibitors | 1 | 2014 | 71 | 0.100 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2014 | 38 | 0.100 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 829 | 0.100 |
Why?
|
| Drug Design | 1 | 2014 | 133 | 0.100 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 67 | 0.100 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2017 | 188 | 0.100 |
Why?
|
| Drug Industry | 1 | 2014 | 56 | 0.100 |
Why?
|
| Hepatitis B | 1 | 2014 | 77 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2016 | 960 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 1917 | 0.100 |
Why?
|
| Disease Management | 1 | 2015 | 358 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2017 | 418 | 0.090 |
Why?
|
| Algorithms | 2 | 2020 | 1953 | 0.090 |
Why?
|
| Acute Kidney Injury | 1 | 2016 | 339 | 0.090 |
Why?
|
| Truth Disclosure | 1 | 2012 | 73 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 304 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1914 | 0.090 |
Why?
|
| Physicians | 1 | 2018 | 682 | 0.090 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 425 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2016 | 822 | 0.080 |
Why?
|
| Recurrence | 1 | 2013 | 1190 | 0.080 |
Why?
|
| Hospitalization | 1 | 2016 | 937 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2015 | 3054 | 0.080 |
Why?
|
| Animals | 2 | 2023 | 28155 | 0.080 |
Why?
|
| Postoperative Period | 1 | 2011 | 315 | 0.080 |
Why?
|
| Decision Trees | 1 | 2020 | 64 | 0.080 |
Why?
|
| Mice | 1 | 2023 | 12269 | 0.080 |
Why?
|
| Precision Medicine | 1 | 2013 | 456 | 0.070 |
Why?
|
| Age Factors | 1 | 2013 | 1906 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 1053 | 0.070 |
Why?
|
| RNA, Viral | 2 | 2021 | 285 | 0.070 |
Why?
|
| Critical Illness | 1 | 2011 | 343 | 0.070 |
Why?
|
| Physician-Patient Relations | 1 | 2012 | 576 | 0.070 |
Why?
|
| Prognosis | 1 | 2015 | 3911 | 0.070 |
Why?
|
| Critical Care | 1 | 2011 | 444 | 0.060 |
Why?
|
| Aged | 5 | 2016 | 20434 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 7061 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 557 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2021 | 1006 | 0.050 |
Why?
|
| Mass Screening | 2 | 2022 | 696 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 1103 | 0.050 |
Why?
|
| Adult | 4 | 2021 | 27918 | 0.050 |
Why?
|
| HIV Infections | 1 | 2013 | 961 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2023 | 145 | 0.050 |
Why?
|
| Dysbiosis | 1 | 2023 | 91 | 0.050 |
Why?
|
| Feces | 1 | 2023 | 360 | 0.040 |
Why?
|
| Risk Factors | 3 | 2021 | 5899 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2009 | 1053 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 291 | 0.030 |
Why?
|
| Chicago | 1 | 2022 | 1464 | 0.030 |
Why?
|
| Graft Survival | 1 | 2021 | 937 | 0.030 |
Why?
|
| Midodrine | 1 | 2016 | 5 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2021 | 485 | 0.030 |
Why?
|
| Vasoconstrictor Agents | 1 | 2016 | 67 | 0.030 |
Why?
|
| Cost Savings | 1 | 2016 | 68 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2016 | 116 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2015 | 188 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 296 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 154 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 711 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 302 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2015 | 135 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 889 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2015 | 168 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 887 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 413 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 492 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2016 | 482 | 0.020 |
Why?
|
| Prevalence | 1 | 2017 | 1321 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 876 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 985 | 0.020 |
Why?
|
| Length of Stay | 1 | 2016 | 828 | 0.020 |
Why?
|
| Base Sequence | 1 | 2015 | 2220 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1931 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 537 | 0.020 |
Why?
|
| Incidence | 1 | 2016 | 1701 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 2910 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2016 | 10164 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 1948 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 1531 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 2585 | 0.020 |
Why?
|
| Phylogeny | 1 | 2015 | 1266 | 0.020 |
Why?
|
| Family Health | 1 | 2009 | 153 | 0.020 |
Why?
|
| Health Education | 1 | 2009 | 105 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 3830 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 6930 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 9606 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 2465 | 0.010 |
Why?
|